Physician profile
Ivor Benjamin
NPI 1114183977
$370,726.06
in general payments reported to CMS, 2019-2025
18 companies · $48K in 2025
The $48K reported for 2025 was more than what 97% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119K · 2020: $11K · 2021: $40K · 2022: $81K · 2023: $37K · 2024: $34K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Travel and Lodging: $20K · Consulting Fee: $8,533 · Food and Beverage: $2,122 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,500.00 |
| Travel and Lodging | $20,296.70 |
| Consulting Fee | $8,533.33 |
| Food and Beverage | $2,122.06 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $244,805.11 | 2020-2025 | Jemperli, Zejula |
| Tesaro, INC. | $118,845.79 | 2019 | |
| Intuitive Surgical, INC. | $5,674.95 | 2019-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $303.28 | 2019-2025 | Lynparza |
| Baxter Healthcare | $226.84 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $198.03 | 2021-2023 | Precisetumor |
| Genmab U.S., INC. | $147.33 | 2021-2024 | Tivdak |
| Clovis Oncology, INC. | $132.43 | 2022 | |
| On Target Laboratories, INC | $125.20 | 2025 | Cytalux |
| Integra Lifesciences Corporation | $107.21 | 2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Certas |
| Merck Sharp & Dohme LLC | $37.88 | 2019 | |
| Amgen INC. | $21.84 | 2019 | |
| Eisai INC. | $20.83 | 2023 | |
| Lilly USA, LLC | $20.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.64 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $14.91 | 2019 | |
| Genzyme Corporation | $13.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivor Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.